Skip to content

Johnson & Johnson JNJ HLD-0915 — Discount rate

Similar metrics at other companies

BioSig Technologies, Inc. logo
STEXDiscount Rate
40.5%
CVS Health logo
CVSLong Term Care — Current discount rate
5.7%+0.1pp
Unum logo
UNMLong-term Care — Current discount rate
5.7%+0.2pp
CorMedix logo
CRMDDiscount Rate
17%
CorMedix logo
CRMDDiscount Rate
17%
Beneficient logo
BENFDiscount rate
20%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$611.36B+73.1%
Enterprise value$644.66B+67.5%
P/E29.1×+13.5×
P/S6.3×+2.4×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept jnj:AcquiredFiniteLivedIntangibleAssetsDiscountRate.

The official record: Johnson & Johnson’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's hld-0915 — discount rate.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's HLD-0915 — discount rate?
Johnson & Johnson (JNJ) reported HLD-0915 — discount rate of 17% in Q4 2025.
What does HLD-0915 — discount rate mean?
The discount rate applied to the projected future cash flows of the HLD-0915 asset to determine its present value. This rate reflects the specific risk profile, cost of capital, and time value of money associated with the development and commercialization of this specific product candidate. It is a critical input in impairment testing and valuation models for R&D-stage assets.